| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended August 31, |
|
|
|
2022 |
|
|
2021 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,522,134 |
|
|
$ |
7,326,516 |
|
PrepaCyte CB |
|
|
21,000 |
|
|
|
18,200 |
|
Public cord blood banking |
|
|
137,825 |
|
|
|
158,936 |
|
Total net revenue |
|
$ |
7,680,959 |
|
|
$ |
7,503,652 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,883,400 |
|
|
$ |
1,943,419 |
|
PrepaCyte CB |
|
|
10,622 |
|
|
|
53,498 |
|
Public cord blood banking |
|
|
454,733 |
|
|
|
462,021 |
|
Total cost of sales |
|
$ |
2,348,755 |
|
|
$ |
2,458,938 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,268,146 |
|
|
$ |
1,941,976 |
|
PrepaCyte CB |
|
|
3,433 |
|
|
|
(42,193 |
) |
Public cord blood banking |
|
|
(317,268 |
) |
|
|
(303,445 |
) |
Total operating profit |
|
$ |
954,311 |
|
|
$ |
1,596,338 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
274,598 |
|
|
$ |
262,229 |
|
PrepaCyte CB |
|
|
6,945 |
|
|
|
6,894 |
|
Public cord blood banking |
|
|
360 |
|
|
|
359 |
|
Total depreciation and amortization |
|
$ |
281,903 |
|
|
$ |
269,482 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
365,349 |
|
|
$ |
335,870 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
365,349 |
|
|
$ |
335,870 |
|
|
|
|
|
|
|
|
|
|
For the nine months ended August 31, |
|
|
|
2022 |
|
|
2021 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
22,159,702 |
|
|
$ |
21,224,033 |
|
PrepaCyte CB |
|
|
75,600 |
|
|
|
56,200 |
|
Public cord blood banking |
|
|
337,405 |
|
|
|
289,231 |
|
Total net revenue |
|
$ |
22,572,707 |
|
|
$ |
21,569,464 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
5,343,455 |
|
|
$ |
5,453,203 |
|
PrepaCyte CB |
|
|
63,934 |
|
|
|
129,581 |
|
Public cord blood banking |
|
|
1,246,108 |
|
|
|
1,111,022 |
|
Total cost of sales |
|
$ |
6,653,497 |
|
|
$ |
6,693,806 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,538,058 |
|
|
$ |
5,743,184 |
|
PrepaCyte CB |
|
|
(9,168 |
) |
|
|
(94,065 |
) |
Public cord blood banking |
|
|
(909,783 |
) |
|
|
(822,452 |
) |
Total operating profit |
|
$ |
3,619,107 |
|
|
$ |
4,826,667 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
818,081 |
|
|
$ |
536,823 |
|
PrepaCyte CB |
|
|
20,834 |
|
|
|
20,683 |
|
Public cord blood banking |
|
|
1,080 |
|
|
|
661 |
|
Total depreciation and amortization |
|
$ |
839,995 |
|
|
$ |
558,167 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
947,968 |
|
|
$ |
957,479 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
947,968 |
|
|
$ |
957,479 |
|
The following table shows the assets by segment as of August 31, 2022 and November 30, 2021:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
August 31, 2022 |
|
|
November 30, 2021 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
56,548,260 |
|
|
$ |
50,170,887 |
|
PrepaCyte CB |
|
|
238,636 |
|
|
|
250,591 |
|
Public cord blood banking |
|
|
9,978,397 |
|
|
|
10,240,598 |
|
Total assets |
|
$ |
66,765,293 |
|
|
$ |
60,662,076 |
|
|